These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2142968)

  • 41. Parenteral and oral cyproterone acetate treatment in severe hirsutism.
    Schmidt JB; Huber J; Spona J
    Gynecol Obstet Invest; 1987; 24(2):125-30. PubMed ID: 3653783
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of reverse sequential anti-androgen therapy (cyproterone acetate and ethinyl estradiol) on hematological parameters.
    Parr JH; Seed M; Godsland I; Wynn V
    J Endocrinol Invest; 1987 Jun; 10(3):237-9. PubMed ID: 2957418
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism.
    Venturoli S; Marescalchi O; Colombo FM; Macrelli S; Ravaioli B; Bagnoli A; Paradisi R; Flamigni C
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1304-10. PubMed ID: 10199771
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monthly cyproterone acetate in the treatment of hirsute women: clinical and laboratory effects.
    Marcondes JA; Wajchenberg BL; Abujamra AC; Luthold WW; Samojlik E; Kirschner MA
    Fertil Steril; 1990 Jan; 53(1):40-4. PubMed ID: 2136835
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cyproterone acetate: a study involving two volunteers with idiopathic hirsutism.
    Barnes EW; Irvine WJ; Hunter WM; Ismail AA
    Clin Endocrinol (Oxf); 1975 Jan; 4(1):65-73. PubMed ID: 1122656
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens.
    Kelekci KH; Kelekci S; Yengel I; Gul S; Yilmaz B
    J Dermatolog Treat; 2012 Jun; 23(3):177-83. PubMed ID: 21254871
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of idiopathic hirsute women with two combinations of cyproterone acetate.
    Salva P; Morer F; Ordoñez J; Rodriguez J
    Int J Clin Pharmacol Res; 1983; 3(2):129-35. PubMed ID: 6237068
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effect of cyproterone acetate on the secretion ACTH, cortisol and testosterone, and on the urinary elimination of 17-OHCS and 17-CS in hirsute females].
    Djurić DS; Manojlović D
    Endocrinologie; 1981; 19(1):59-63. PubMed ID: 6270779
    [No Abstract]   [Full Text] [Related]  

  • 49. Steroid inhibitors of androgen-potentiated actions on skin.
    Ebling FJ; Randall VA
    J Steroid Biochem; 1983 Jul; 19(1B):587-90. PubMed ID: 6224973
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The evaluation of the role of androgens in hirsutism and the use of a new anti-androgen "cyproterone acetate" for therapy.
    Ismail AA; Davidson DW; Souka AR; Barnes EW; Irvine WJ; Kilimnik H; Vanderbeeken Y
    J Clin Endocrinol Metab; 1974 Jul; 39(1):81-95. PubMed ID: 4835125
    [No Abstract]   [Full Text] [Related]  

  • 51. Therapeutic alternatives for the hirsute woman.
    Bassaw B; Maharaj R; Ali A; Roopnarinesingh S
    West Indian Med J; 1992 Mar; 41(1):12-4. PubMed ID: 1533080
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women: the effect of cyproterone acetate-ethinyl estradiol treatment.
    Luboshitzky R; Herer P; Shen-Orr Z
    Exp Clin Endocrinol Diabetes; 2004 Feb; 112(2):102-7. PubMed ID: 15031776
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
    Falsetti L; Dordoni D; Gastaldi C; Gastaldi A
    Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism.
    O'Brien RC; Cooper ME; Murray RM; Seeman E; Thomas AK; Jerums G
    J Clin Endocrinol Metab; 1991 May; 72(5):1008-13. PubMed ID: 1827125
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Treatment of hirsutism with peripherally acting antiandrogens. Experiences with cyproterone acetate].
    Vinueza G; Zárate A; Canales ES
    Ginecol Obstet Mex; 1980 Nov; 48(289):303-9. PubMed ID: 6454611
    [No Abstract]   [Full Text] [Related]  

  • 56. [Value of cyproterone acetate in the treatment of hirsutism].
    Baron J; Chwalisz K; Warenik-Szymankiewicz A
    Ginekol Pol; 1982 Apr; 53(4):283-7. PubMed ID: 6216148
    [No Abstract]   [Full Text] [Related]  

  • 57. [Evaluation of cyproterone acetate in the treatment of hirsutism].
    Más Díaz J; Padrón Durán RS; Licea Puig M
    Med Clin (Barc); 1985 Sep; 85(8):313-5. PubMed ID: 2933566
    [No Abstract]   [Full Text] [Related]  

  • 58. Time dependency and reversibility of the effects of exclusive cyproterone acetate therapy on pituitary adrenal function in hirsute women.
    Salvador J; Barbería JJ; Martí J; Forga L; Saavedra J; Moncada E
    Acta Endocrinol (Copenh); 1985 Oct; 110(2):164-9. PubMed ID: 2998129
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism.
    Lumachi F; Rondinone R
    Fertil Steril; 2003 Apr; 79(4):942-6. PubMed ID: 12749435
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism.
    Erenus M; Yücelten D; Gürbüz O; Durmuşoğlu F; Pekin S
    Fertil Steril; 1996 Aug; 66(2):216-9. PubMed ID: 8690104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.